Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
IOVA Stock Forecast 2026-2027
$3.86
Current Price
$1.59B
Market Cap
Buy 8
Hold 3
Sell 0
Wall St Analyst Ratings
Distance to IOVA Price Targets
+314.5%
To High Target of $16.00
+146.1%
To Median Target of $9.50
+3.6%
To Low Target of $4.00
IOVA Price Momentum
+4.3%
1 Week Change
-0.3%
1 Month Change
+26.1%
1 Year Change
+41.4%
Year-to-Date Change
-31.4%
From 52W High of $5.63
+135.4%
From 52W Low of $1.64
📊 TOP ANALYST CALLS
Did IOVA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Iovance is one of their latest high-conviction picks.
Latest IOVA Stock Price Targets & Analyst Predictions
Based on our analysis of 21 Wall Street analysts, IOVA has a bullish consensus with a median price target of $9.50 (ranging from $4.00 to $16.00). The overall analyst rating is Strong Buy (8.5/10). Currently trading at $3.86, the median forecast implies a 146.1% upside. This outlook is supported by 8 Buy, 3 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Geulah Livshits at Chardan Capital, projecting a 314.5% upside. Conversely, the most conservative target is provided by David Dai at UBS, suggesting a 3.6% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
IOVA Analyst Ratings
8
Buy
3
Hold
0
Sell
IOVA Price Target Range
Low
$4.00
Average
$9.50
High
$16.00
Current: $3.86
Latest IOVA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for IOVA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $16.00 |
| Mar 5, 2026 | UBS | David Dai | Neutral | Maintains | $4.00 |
| Mar 3, 2026 | Citizens | Reni J. Benjamin | Market Outperform | Upgrade | $5.00 |
| Feb 25, 2026 | Barclays | Etzer Darout | Overweight | Maintains | $11.00 |
| Feb 25, 2026 | Citizens | Reni J. Benjamin | Market Outperform | Upgrade | $5.00 |
| Dec 17, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $10.00 |
| Nov 24, 2025 | Barclays | Etzer Darout | Overweight | Maintains | $9.00 |
| Nov 6, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $17.00 |
| Oct 29, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $9.00 |
| Aug 19, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Reiterates | $20.00 |
| Aug 8, 2025 | Wells Fargo | Yanan Zhu | Overweight | Maintains | $14.00 |
| Aug 8, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $20.00 |
| Jul 23, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
| May 16, 2025 | UBS | David Dai | Neutral | Downgrade | $2.00 |
| May 12, 2025 | Goldman Sachs | Andrea Tan | Buy | Maintains | $8.00 |
| May 12, 2025 | Mizuho | Mara Goldstein | Outperform | Maintains | $10.00 |
| May 12, 2025 | Barclays | Peter Lawson | Overweight | Maintains | $4.00 |
| May 9, 2025 | JMP Securities | Reni Benjamin | Market Perform | Downgrade | $N/A |
| May 9, 2025 | Chardan Capital | Geulah Livshits | Buy | Maintains | $25.00 |
| May 9, 2025 | HC Wainwright & Co. | Joseph Pantginis | Buy | Maintains | $20.00 |
Iovance Biotherapeutics, Inc. (IOVA) Competitors
The following stocks are similar to Iovance based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iovance Biotherapeutics, Inc. (IOVA) Financial Data
Iovance Biotherapeutics, Inc. has a market capitalization of $1.59B with a P/E ratio of -3.5x. The company generates $263.50M in trailing twelve-month revenue with a -148.4% profit margin.
Revenue growth is +17.7% quarter-over-quarter, while maintaining an operating margin of -84.7% and return on equity of -55.5%.
Valuation Metrics
Market Cap
$1.59B
Enterprise Value
$1.33B
P/E Ratio
-3.5x
PEG Ratio
0.1x
Price/Sales
6.0x
Growth & Margins
Revenue Growth (YoY)
+17.7%
Gross Margin
+50.3%
Operating Margin
-84.7%
Net Margin
-148.4%
EPS Growth
+17.7%
Financial Health
Cash/Price Ratio
+18.7%
Current Ratio
3.2x
Debt/Equity
7.1x
ROE
-55.5%
ROA
-27.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Iovance Biotherapeutics, Inc. (IOVA) Business Model
About Iovance Biotherapeutics, Inc.
What They Do
Develops tumor-infiltrating lymphocyte therapies for cancer.
Business Model
The company operates on a commercial-stage model, generating revenue primarily through the sale of its FDA-approved therapy, Amtagvi (lifileucel), for treating unresectable or metastatic melanoma. It further aims to monetize its innovative TIL therapies by advancing clinical programs for various solid tumors and leveraging partnerships with research institutions and pharmaceutical companies.
Additional Information
Iovance's manufacturing is conducted at a state-of-the-art facility in Philadelphia, ensuring high-quality production of its therapies. The company is exploring treatments for other cancers, including cervical and non-small cell lung cancer, positioning itself as a leader in the biopharmaceutical field with a focus on personalized medicine.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
975
CEO
Dr. Frederick G. Vogt Esq., J.D., Ph.D.
Country
United States
IPO Year
2017
Website
www.iovance.comIovance Biotherapeutics, Inc. (IOVA) Latest News & Analysis
Latest News
Quick Summary
Iovance Biotherapeutics approved inducement stock options for 135,470 shares to twelve new non-executive employees as of April 16, 2026.
Why It Matters
The grant of stock options to new employees can signal confidence in the company's future, potentially boosting employee motivation and aligning their interests with shareholders.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Iovance Biotherapeutics' key product is experiencing rapid sales growth, supported by international approvals and label expansions, indicating potential continued momentum.
Why It Matters
Rapidly growing sales and international approvals for Iovance Biotherapeutics' product suggest strong revenue potential, indicating positive growth prospects for investors.
Source: The Motley Fool
Market Sentiment:
Positive
Quick Summary
Iovance Biotherapeutics is poised for growth with strong Amtagvi sales and pipeline advancements. Real-world data shows improved outcomes, with key catalysts expected in 2024.
Why It Matters
Iovance Biotherapeutics shows strong growth potential with robust real-world data and upcoming pivotal trials, enhancing confidence in future revenue and market position.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. Investors may want to monitor upcoming developments and market reactions for future stock performance.
Why It Matters
The timing of Iovance's earnings report could signal upcoming volatility or trends in stock performance, influencing investment decisions and market sentiment.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
The oncology medicine market is projected to reach $366 billion in eight years, with biotech firms focusing on niche treatments for specific cancer types.
Why It Matters
The expected growth of the oncology market to $366 billion highlights significant investment opportunities in biotech firms focused on cancer treatments, driving potential returns for investors.
Source: MarketBeat
Market Sentiment:
Neutral
Quick Summary
Iovance Biotherapeutics, Inc. (IOVA) presented at the Barclays 28th Annual Global Healthcare Conference, sharing insights on its developments and strategies.
Why It Matters
Iovance's presentation at a major healthcare conference could signal advancements in its therapies, influencing investor sentiment and stock performance based on market expectations.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About IOVA Stock
What is Iovance Biotherapeutics, Inc.'s (IOVA) stock forecast for 2026?
Based on our analysis of 21 Wall Street analysts, Iovance Biotherapeutics, Inc. (IOVA) has a median price target of $9.50. The highest price target is $16.00 and the lowest is $4.00.
Is IOVA stock a good investment in 2026?
According to current analyst ratings, IOVA has 8 Buy ratings, 3 Hold ratings, and 0 Sell ratings. The stock is currently trading at $3.86. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for IOVA stock?
Wall Street analysts predict IOVA stock could reach $9.50 in the next 12 months. This represents a 146.1% increase from the current price of $3.86. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iovance Biotherapeutics, Inc.'s business model?
The company operates on a commercial-stage model, generating revenue primarily through the sale of its FDA-approved therapy, Amtagvi (lifileucel), for treating unresectable or metastatic melanoma. It further aims to monetize its innovative TIL therapies by advancing clinical programs for various solid tumors and leveraging partnerships with research institutions and pharmaceutical companies.
What is the highest forecasted price for IOVA Iovance Biotherapeutics, Inc.?
The highest price target for IOVA is $16.00 from Geulah Livshits at Chardan Capital, which represents a 314.5% increase from the current price of $3.86.
What is the lowest forecasted price for IOVA Iovance Biotherapeutics, Inc.?
The lowest price target for IOVA is $4.00 from David Dai at UBS, which represents a 3.6% increase from the current price of $3.86.
What is the overall IOVA consensus from analysts for Iovance Biotherapeutics, Inc.?
The overall analyst consensus for IOVA is bullish. Out of 21 Wall Street analysts, 8 rate it as Buy, 3 as Hold, and 0 as Sell, with a median price target of $9.50.
How accurate are IOVA stock price projections?
Stock price projections, including those for Iovance Biotherapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 19, 2026 7:26 AM UTC